Cannabidiol before seizures in infants with Sturge-Weber syndrome
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether starting the medication Epidiolex (a purified form of cannabidiol) before any seizures occur can help prevent or delay seizures in infants with Sturge-Weber syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must have Sturge-Weber syndrome.
- Age must be between 1 and 18 months.
- Brain scans must show involvement in 3 or more brain areas or both sides of the brain.
- The child must not have had any seizures yet.
- A parent or guardian must sign a consent form.
- The child must not be taking any seizure medications, aspirin, or other cannabis products, and must not have certain liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral cannabidiol medicine (Epidiolex) for children whose seizures are not controlled by other treatments. It aims to see if adding this drug can reduce seizure frequency.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This trial tests a way of slowly increasing the dose of a CBD medicine (called Epidiolex) in adults with a severe type of epilepsy called Lennox-Gastaut syndrome (LGS). The goal is to find the best, most comfortable dose that helps reduce seizures.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
Hear when a new Sturge - Weber Syndrome (SWS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.